559 related articles for article (PubMed ID: 30990879)
21. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
[TBL] [Abstract][Full Text] [Related]
22. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
[TBL] [Abstract][Full Text] [Related]
23. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
[TBL] [Abstract][Full Text] [Related]
24. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
Tsvankin V; Hashizume R; Katagi H; Herndon JE; Lascola C; Venkatraman TN; Picard D; Burrus B; Becher OJ; Thompson EM
Neurosurgery; 2020 May; 86(5):742-751. PubMed ID: 31225627
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
26. Histone H3.3K27M Represses
Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
[TBL] [Abstract][Full Text] [Related]
27. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
Dalle Ore C; Coleman C; Gupta N; Mueller S
Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
[TBL] [Abstract][Full Text] [Related]
28. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
29. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.
Buczkowicz P; Bartels U; Bouffet E; Becher O; Hawkins C
Acta Neuropathol; 2014 Oct; 128(4):573-81. PubMed ID: 25047029
[TBL] [Abstract][Full Text] [Related]
30. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.
Saratsis AM; Kambhampati M; Snyder K; Yadavilli S; Devaney JM; Harmon B; Hall J; Raabe EH; An P; Weingart M; Rood BR; Magge SN; MacDonald TJ; Packer RJ; Nazarian J
Acta Neuropathol; 2014; 127(6):881-95. PubMed ID: 24297113
[TBL] [Abstract][Full Text] [Related]
31. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.
Panditharatna E; Yaeger K; Kilburn LB; Packer RJ; Nazarian J
Cancer Genet; 2015; 208(7-8):367-73. PubMed ID: 26206682
[TBL] [Abstract][Full Text] [Related]
33. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.
Lewis NA; Klein RH; Kelly C; Yee J; Knoepfler PS
Epigenetics Chromatin; 2022 May; 15(1):18. PubMed ID: 35590427
[TBL] [Abstract][Full Text] [Related]
34. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
[TBL] [Abstract][Full Text] [Related]
35. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
36. The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma.
Yadavilli S; Scafidi J; Becher OJ; Saratsis AM; Hiner RL; Kambhampati M; Mariarita S; MacDonald TJ; Codispoti KE; Magge SN; Jaiswal JK; Packer RJ; Nazarian J
Oncotarget; 2015 May; 6(14):12141-55. PubMed ID: 25987129
[TBL] [Abstract][Full Text] [Related]
37. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
[TBL] [Abstract][Full Text] [Related]
38. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
Werbrouck C; Evangelista CCS; Lobón-Iglesias MJ; Barret E; Le Teuff G; Merlevede J; Brusini R; Kergrohen T; Mondini M; Bolle S; Varlet P; Beccaria K; Boddaert N; Puget S; Grill J; Debily MA; Castel D
Clin Cancer Res; 2019 Nov; 25(22):6788-6800. PubMed ID: 31481512
[TBL] [Abstract][Full Text] [Related]
39. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
40. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
Larson JD; Kasper LH; Paugh BS; Jin H; Wu G; Kwon CH; Fan Y; Shaw TI; Silveira AB; Qu C; Xu R; Zhu X; Zhang J; Russell HR; Peters JL; Finkelstein D; Xu B; Lin T; Tinkle CL; Patay Z; Onar-Thomas A; Pounds SB; McKinnon PJ; Ellison DW; Zhang J; Baker SJ
Cancer Cell; 2019 Jan; 35(1):140-155.e7. PubMed ID: 30595505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
